Disrupting drug Resistance using Innovative Design (JPIAMR-DRUID)

The French National Research Agency, in partnership with seventeen countries (Belgium, Canada, Czech Republic, Denmark, Estonia, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Moldova, Poland, Spain, Sweden, Switzerland, United Kingdom) is launching the fourteenth call for proposals under the umbrella of the JPIAMR. The initiative aims to promote international research on antimicrobial resistance. The total budget for this action is 18.9 million euros.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents. Proposals should focus on licenced antimicrobials agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should focus on one or more of the One Health settings (humans, animals, plants).

Consortia must include a minimum of 3 eligible partners asking for funding from 3 different countries participating in the call, including at least 2 European countries or associate. The maximum number of partners allowed (including non-funded partners) is 6. The maximum number of partners can be increased to 7 if the consortium includes a company, or a partner coming from low- or middle-income countries, Lithuania or Poland. The budget of non-funded partners shall not exceed 30% of the total transnational project budget requested. ANR will only fund the French partners of the selected projects. Selected projects will be initially funded for a period of up to three years. In agreement with ANR policy, funded researchers should respect the guidelines of the Nagoya protocol and consider open access publication of their results. A detailed description of the eligibility requirements can be found on the JPIAMR Website.